Glycosylation is the reaction in which a carbohydrate is attached to a hydroxyl or other functional group of another molecule. Peptides have promising therapeutic potential in the treatment of several diseases, as they show high activity, target specificity, low toxicity, and minimal non-specific and drug–drug interactions. Several attempts were made to improve the pharmacological properties of peptide drugs for the efficient delivery of these drugs to the targeted sites. However, this is not yet achieved due to the poor physicochemical properties of peptides and this led to the discovery of glycosylated peptides.

Request Sample Copy of the Business Report :https://www.worldwidemarketreports.com/sample/166841

Key features of glycosylated peptide drugs include increased half-life, provides extended dosing duration, better solubility, and improved response to the therapy. Some of the advantages of peptide glycosylation include targeting specific organs and enhancing biodistribution in tissues, improving penetration through biological membranes, and increasing metabolic stability and lowering the clearance rate.

The benefits of these peptides that show high biological activity, availability of innovative peptides in the market, and rise in incidence of chronic diseases worldwide are some of the major factors that drive growth of glycosylated peptide market. The ongoing research and development activities and increasing investments by the pharmaceutical companies also fuel growth of the market.

However, the intrinsic complexity for manufacturing and high cost of the active pharmaceutical ingredient (API) are factors that will restrain growth of glycosylated peptide market.

Key Developments in Glycosylated Peptide Market

Key players are adopting various strategies such as mergers, acquisitions, new product launches, expansions, collaborations, partnerships, approvals, and joint ventures to retain its position in the glycosylated peptide market. On April 17, 2018, Medtronic expanded its focus on Interventional Oncology with the U.S. launch of OptiSphere (TM) Embolization Spheres. On April 18, 2018, Sandoz signed an agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders. Furthermore, on April 10, 2018, Medtronic announced the CE Mark and European launch of the Visualase (TM) MRI-Guided Laser Ablation System.

Get discount on this report : https://www.worldwidemarketreports.com/discount/166841

Some of the key players operating in the glycosylated peptide market include Sandoz International GmbH, Pfizer Inc. Roche Ltd, Teva Pharmaceuticals Industries Ltd, Celltrion Inc., Biocon Ltd., Dr. Reddys Laboratories Ltd, Medtronic plc, Cipla Inc, and Bachem Americas, Inc.

**If you have any special requirements, please let us know and we will offer you the report as you want.

About WMR :

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

Contact Us:

Mr. Shah

Worldwide Market Reports

1001 4th Ave,

U.S

Tel: +1 415 871 0703

Email: [email protected]

WEBSITE : https://www.worldwidemarketreports.com/